{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:51:52Z","timestamp":1791359512790,"version":"4.3.1"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Immune checkpoint blockade targeting PD-1\/PD-L1 has reshaped cancer therapy across multiple tumor types. However, primary and acquired resistance remain major barriers to durable clinical benefit. Increasing evidence indicates that immunotherapy resistance is not driven by isolated molecular alterations, but by coordinated changes involving tumor-intrinsic immune escape, immunosuppressive tumor microenvironments, systemic inflammatory remodeling, and adaptive biomarker evolution under therapeutic pressure. This review focuses on pan-cancer biomarkers of immune therapy resistance from the perspective of mechanisms and clinical translation. First, we summarize targetable biomarker classes that link resistance biology to therapeutic sensitization across cancers, including transcription factors, genomic alterations, immune checkpoint proteins and metabolic regulators. For each class, we highlight representative cancer types in which experimental or clinical evidence supports their role in immunotherapy resistance. Second, we discuss the mechanistic basis of resistance-associated biomarkers, emphasizing antigen presentation defects, impaired interferon signaling, oncogenic pathway activation, T-cell exhaustion, myeloid and stromal immunosuppression, metabolic reprogramming, and dynamic systemic immune remodeling. These mechanisms provide a biological perspective for interpreting biomarkers not only as predictors of treatment response, but also as functional indicators of resistance evolution. By integrating biomarker classification, resistance mechanisms, and therapeutic sensitization strategies, this review aims to provide a new perspective for using pan-cancer resistance biomarkers to guide rational combination immunotherapy and improve precision cancer treatment.<\/jats:p>","DOI":"10.3389\/fcell.2026.1895670","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:00Z","timestamp":1791357180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pan-cancer biomarkers of immune therapy resistance: mechanisms and clinical translation"],"prefix":"10.3389","volume":"14","author":[{"given":"Chao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gastric Surgery, Liaoning Cancer Hospital & Institute","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Liaoning Cancer Hospital & Institute","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e2518440","DOI":"10.1001\/jamanetworkopen.2025.18440","article-title":"Durvalumab alone or combined with novel agents for unresectable stage III non-small cell lung cancer: update from the COAST randomized clinical trial","volume":"8","author":"Aggarwal","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/1078-0432.CCR-25-2013","article-title":"IK-175, an oral aryl hydrocarbon receptor inhibitor, alone and with nivolumab in patients with advanced solid tumors and urothelial carcinoma","volume":"32","author":"Aggen","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (checkMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.1182\/bloodadvances.2024014654","article-title":"Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory hodgkin lymphoma","volume":"9","author":"Armand","year":"2025","journal-title":"Blood Adv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3389\/fimmu.2020.01243","article-title":"Tryptophan catabolism as immune mechanism of primary resistance to Anti-PD-1","volume":"11","author":"Botticelli","year":"2020","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/2326-6066.CIR-20-0085","article-title":"Immunosuppressive myeloid cells induce nitric oxide-dependent DNA damage and p53 pathway activation in CD8(+) T cells","volume":"9","author":"Cartwright","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa2518245","article-title":"Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma","volume":"395","author":"Choueiri","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1575181","DOI":"10.3389\/fimmu.2025.1575181","article-title":"Selective inhibition of canonical STAT3 signaling suppresses K-ras mutant lung tumorigenesis and reinvigorates anti-tumor immunity","volume":"16","author":"Clowers","year":"2025","journal-title":"Front. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma","volume":"26","author":"Courtney","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e003549","DOI":"10.1136\/jitc-2021-003549","article-title":"Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer","volume":"10","author":"De Sanctis","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.immuni.2016.10.021","article-title":"Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells","volume":"45","author":"De Simone","year":"2016","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","first-page":"109071","DOI":"10.1016\/j.celrep.2021.109071","article-title":"Pharmacological wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy","volume":"35","author":"DeVito","year":"2021","journal-title":"Cell Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00018-025-05642-8","article-title":"Targeting HIF-2\u03b1 in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade","volume":"82","author":"Espinoza","year":"2025","journal-title":"Cell Mol. Life Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/0008-5472.CAN-14-1491","article-title":"l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells","volume":"75","author":"Fletcher","year":"2015","journal-title":"Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.3390\/cancers15092607","article-title":"BRAF V600-Mutated metastatic melanoma and targeted therapy resistance: an update of the current knowledge","volume":"15","author":"Florent","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","article-title":"Interruption of the intratumor CD8(+) T cell:treg crosstalk improves the efficacy of PD-1 immunotherapy","volume":"42","author":"Geels","year":"2024","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"B26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ccell.2020.11.015","article-title":"Conserved Interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"39","author":"Grasso","year":"2021","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","article-title":"Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype","volume":"14","author":"Hiltbrunner","year":"2023","journal-title":"Nat. Commun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.actbio.2025.01.040","article-title":"Lung-targeted delivery of PTEN mRNA combined with anti-PD-1-mediated immunotherapy for in Situ lung cancer treatment","volume":"194","author":"Hu","year":"2025","journal-title":"Acta Biomater."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"654749","DOI":"10.3389\/fimmu.2021.654749","article-title":"Targeting STAT3 abrogates Tim-3 upregulation of adaptive resistance to PD-1 blockade on regulatory T cells of melanoma","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (checkMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod. Pathol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1158\/1078-0432.CCR-16-3146","article-title":"PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors","volume":"23","author":"Kluger","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.3390\/cancers14102486","article-title":"Resistance to gemcitabine in pancreatic ductal adenocarcinoma: a physiopathologic and pharmacologic review","volume":"14","author":"Koltai","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1038\/s41591-026-04475-7","article-title":"Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial","volume":"32","author":"Lim","year":"2026","journal-title":"Nat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"eaba9772","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","article-title":"Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer","volume":"3","author":"Liu","year":"2022","journal-title":"Nat. Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-Year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2022.01.027","article-title":"HIF-1\u03b1 inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer","volume":"531","author":"Luo","year":"2022","journal-title":"Cancer Lett."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1158\/1535-7163.MCT-21-0984","article-title":"Discovery and characterization of a novel aryl hydrocarbon receptor inhibitor, IK-175, and its inhibitory activity on tumor immune suppression","volume":"21","author":"McGovern","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00321","article-title":"Majority of B2M-Mutant and -Deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high","volume":"3","author":"Middha","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21873\/cdp.10409","article-title":"Tumor \u03b2-Catenin expression associated with poor prognosis to Anti-PD-1 antibody monotherapy in non-small cell lung cancer","volume":"5","author":"Muto","year":"2025","journal-title":"Cancer Diagn Progn."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1158\/2326-6066.CIR-22-0326","article-title":"Coexisting alterations of MHC class I antigen presentation and IFN\u03b3 signaling mediate acquired resistance of melanoma to Post-PD-1 immunotherapy","volume":"10","author":"Nielsen","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e004605","DOI":"10.1136\/jitc-2022-004605","article-title":"Tumor-associated tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells","volume":"10","author":"Noyes","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41588-025-02193-3","article-title":"High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer","volume":"57","author":"Oliveira","year":"2025","journal-title":"Nat. Genet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (checkMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"B57","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.annonc.2022.07.001","article-title":"Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors","volume":"33","author":"Peyraud","year":"2022","journal-title":"Ann. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3109\/08820139.2012.680634","article-title":"Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives","volume":"41","author":"Raber","year":"2012","journal-title":"Immunol. Invest."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","article-title":"L-arginine availability regulates T-lymphocyte cell-cycle progression","volume":"109","author":"Rodriguez","year":"2007","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e156774","DOI":"10.1172\/JCI156774","article-title":"HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy","volume":"132","author":"Salman","year":"2022","journal-title":"J. Clin. Invest."},{"key":"B65","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"60975","DOI":"10.18632\/oncotarget.17689","article-title":"Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer","volume":"8","author":"Shen","year":"2017","journal-title":"Oncotarget"},{"key":"B67","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"B68","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e006728","DOI":"10.1136\/jitc-2023-006728","article-title":"Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2\/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes","volume":"11","author":"Solvay","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3322\/caac.21844","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1158\/1535-7163.MCT-12-1087","article-title":"Targeting blockage of STAT3 in hepatocellular carcinoma cells augments NK cell functions via reverse hepatocellular carcinoma-induced immune suppression","volume":"12","author":"Sun","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"eabc6424","DOI":"10.1126\/sciimmunol.abc6424","article-title":"Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape","volume":"6","author":"Takeuchi","year":"2021","journal-title":"Sci. Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B76","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","article-title":"Phase I trial of TTI-101, a first-in-class oral inhibitor of STAT3, in patients with advanced solid tumors","volume":"31","author":"Tsimberidou","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e001689","DOI":"10.1136\/jitc-2020-001689","article-title":"Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy","volume":"8","author":"Turiello","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","article-title":"Response rates to Anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase","volume":"7","author":"Valero","year":"2021","journal-title":"JAMA Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1809947","DOI":"10.1080\/2162402X.2020.1809947","article-title":"\u03b2-Catenin inhibition shapes tumor immunity and synergizes with immunotherapy in colorectal cancer","volume":"9","author":"Wang","year":"2020","journal-title":"Oncoimmunology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"B81","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"10039","DOI":"10.1038\/s41467-025-65945-z","article-title":"Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation","volume":"16","author":"Wu","year":"2025","journal-title":"Nat. Commun."},{"key":"B84","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"216824","DOI":"10.1016\/j.canlet.2024.216824","article-title":"Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming","volume":"589","author":"Yu","year":"2024","journal-title":"Cancer Lett."},{"key":"B86","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/CJI.0000000000000417","article-title":"B2M and JAK1\/2-mutated MSI-H colorectal carcinomas can benefit from Anti-PD-1 therapy","volume":"45","author":"Zhang","year":"2022","journal-title":"J. Immunother."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e70921","DOI":"10.1002\/cam4.70921","article-title":"Strategies beyond 3rd EGFR-TKI acquired resistance: opportunities and challenges","volume":"14","author":"Zhou","year":"2025","journal-title":"Cancer Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"104055","DOI":"10.1016\/j.redox.2026.104055","article-title":"DMNQ induces ferroptosis and augments the efficacy of anti-PD-L1 immunotherapy in gastric cancer via the STAT3\/SLC1A4 axis to mediate cysteine metabolism reprogramming","volume":"90","author":"Zhu","year":"2026","journal-title":"Redox Biol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1895670\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:02Z","timestamp":1791357182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1895670\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":88,"alternative-id":["10.3389\/fcell.2026.1895670"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1895670","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1895670"}}